NCT05060198View on ClinicalTrials.gov

Therapeutic Efficacy Study of AL and DP in Western Kenya

NACompletedINTERVENTIONAL
Enrollment

340

Participants

Timeline

Start Date

June 17, 2016

Primary Completion Date

March 13, 2017

Study Completion Date

December 31, 2020

Conditions
Malaria,Falciparum
Interventions
DRUG

Artemether-lumefantrine (AL)

AL is the current first-line antimalarial in Kenya, per Kenya Ministry of Health.

DRUG

Dihydroartemisinin-piperaquine (DP)

DP is the current second-line antimalarial in Kenya, per Kenya Ministry of Health.

Sponsors
All Listed Sponsors
collaborator

Centers for Disease Control and Prevention

FED

lead

Kenya Medical Research Institute

OTHER